Format

Send to

Choose Destination
AIDS Behav. 2018 Nov;22(11):3627-3636. doi: 10.1007/s10461-018-2102-9.

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.

Author information

1
HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA. Cr2857@cumc.columbia.edu.
2
Program for the Study of LGBT Health at the New York State Psychiatric Institute/Columbia Psychiatry and the Columbia University School of Nursing, New York, NY, USA.
3
Columbia University Mailman School of Public Health, New York, NY, USA.
4
HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.
5
CUNY School of Public Health, New York, NY, USA.
6
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
7
Department of Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
8
Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Abstract

Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City's perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.

KEYWORDS:

Barriers; Facilitators; HIV prevention; PrEP; Transgender women; Transwomen

PMID:
29589137
PMCID:
PMC6160363
DOI:
10.1007/s10461-018-2102-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center